Roundview Capital LLC Bristol Myers Squibb CO Transaction History

Roundview Capital LLC

  • $1.35 Billion
  • Q3 2024

A detailed history of Roundview Capital LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Roundview Capital LLC holds 11,321 shares of BMY stock, worth $670,995. This represents 0.04% of its overall portfolio holdings.

Number of Shares
11,321
Previous 13,922 18.68%
Holding current value
$670,995
Previous $578,000 1.21%
% of portfolio
0.04%
Previous 0.05%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$39.66 - $51.75 $103,155 - $134,601
-2,601 Reduced 18.68%
11,321 $585,000
Q2 2024

Aug 09, 2024
SELL
$40.25 - $52.99 $46,730 - $61,521
-1,161 Reduced 7.7%
13,922 $578,000
Q1 2024

May 06, 2024
SELL
$47.98 - $54.4 $195,326 - $221,462
-4,071 Reduced 21.25%
15,083 $817,000
Q4 2023

Feb 12, 2024
SELL
$48.48 - $57.85 $452,851 - $540,376
-9,341 Reduced 32.78%
19,154 $982,000
Q3 2023

Nov 13, 2023
SELL
$57.89 - $64.73 $155,897 - $174,317
-2,693 Reduced 8.63%
28,495 $1.65 Million
Q2 2023

Aug 09, 2023
SELL
$63.71 - $70.74 $7,454 - $8,276
-117 Reduced 0.37%
31,188 $1.99 Million
Q1 2023

May 09, 2023
SELL
$65.71 - $74.53 $3,679 - $4,173
-56 Reduced 0.18%
31,305 $2.17 Million
Q4 2022

Feb 13, 2023
BUY
$68.48 - $81.09 $245,774 - $291,032
3,589 Added 12.92%
31,361 $2.26 Million
Q3 2022

Nov 10, 2022
BUY
$0.13 - $76.84 $452 - $267,249
3,478 Added 14.32%
27,772 $1.97 Million
Q2 2022

Aug 11, 2022
SELL
$72.62 - $79.98 $24,472 - $26,953
-337 Reduced 1.37%
24,294 $1.87 Million
Q1 2022

May 11, 2022
BUY
$61.48 - $73.72 $69,779 - $83,672
1,135 Added 4.83%
24,631 $1.8 Million
Q4 2021

Feb 10, 2022
SELL
$53.63 - $62.52 $837,325 - $976,124
-15,613 Reduced 39.92%
23,496 $1.47 Million
Q3 2021

Nov 10, 2021
BUY
$59.17 - $69.31 $178,279 - $208,831
3,013 Added 8.35%
39,109 $2.31 Million
Q2 2021

Aug 10, 2021
BUY
$61.91 - $67.42 $681 - $741
11 Added 0.03%
36,096 $2.41 Million
Q1 2021

May 14, 2021
BUY
$59.34 - $66.74 $40,351 - $45,383
680 Added 1.92%
36,085 $2.28 Million
Q4 2020

Feb 08, 2021
SELL
$57.74 - $65.43 $55,834 - $63,270
-967 Reduced 2.66%
35,405 $2.2 Million
Q3 2020

Nov 05, 2020
SELL
$57.43 - $63.64 $156,496 - $173,419
-2,725 Reduced 6.97%
36,372 $2.19 Million
Q2 2020

Aug 13, 2020
BUY
$54.82 - $64.09 $131,184 - $153,367
2,393 Added 6.52%
39,097 $2.3 Million
Q1 2020

May 11, 2020
BUY
$46.4 - $67.43 $484,926 - $704,710
10,451 Added 39.81%
36,704 $2.05 Million
Q4 2019

Feb 10, 2020
BUY
$49.21 - $64.19 $233,550 - $304,645
4,746 Added 22.07%
26,253 $1.69 Million
Q3 2019

Nov 12, 2019
SELL
$42.77 - $50.71 $91,313 - $108,265
-2,135 Reduced 9.03%
21,507 $1.09 Million
Q2 2019

Aug 12, 2019
SELL
$44.62 - $49.34 $273,520 - $302,454
-6,130 Reduced 20.59%
23,642 $1.07 Million
Q1 2019

May 09, 2019
SELL
$45.12 - $53.8 $36,817 - $43,900
-816 Reduced 2.67%
29,772 $1.42 Million
Q4 2018

Feb 13, 2019
BUY
$48.76 - $63.23 $75,041 - $97,310
1,539 Added 5.3%
30,588 $1.59 Million
Q3 2018

Nov 07, 2018
BUY
$55.19 - $62.25 $6,126 - $6,909
111 Added 0.38%
29,049 $1.8 Million
Q2 2018

Aug 10, 2018
BUY
$50.53 - $62.98 $750,623 - $935,567
14,855 Added 105.48%
28,938 $1.6 Million
Q1 2018

May 14, 2018
SELL
$59.92 - $68.98 $84,487 - $97,261
-1,410 Reduced 9.1%
14,083 $891,000
Q4 2017

Feb 07, 2018
BUY
$59.94 - $65.35 $181,798 - $198,206
3,033 Added 24.34%
15,493 $949,000
Q3 2017

Nov 13, 2017
SELL
$55.23 - $63.74 $50,811 - $58,640
-920 Reduced 6.88%
12,460 $794,000
Q3 2017

Nov 13, 2017
BUY
$55.23 - $63.74 $738,977 - $852,841
13,380
13,380 $746,000

Others Institutions Holding BMY

# of Institutions
2,536
Shares Held
1.47B
Call Options Held
31.6M
Put Options Held
35M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Roundview Capital LLC Portfolio

Follow Roundview Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roundview Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Roundview Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email